Covidien, a US-based provider of healthcare products, and Nuvo Research, a Canadian drug development company, have received the FDA’s approval of its new drug application for Pennsaid topical solution 1.5% w/w. Pennsaid topical solution is a non-steroidal anti-inflammatory drug (NSAID) used for the treatment of the signs and symptoms of osteoarthritis of the knee. Covidien is responsible for all US commercialization activities, and is responsible for the clinical development of Pennsaid Plus.